Press Releases
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jun 21, 2018Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute and Massachusetts General Hospital officially activated and recruiting patients for Phase 2 open-label trial of PCM-075 and abiraterone acetate (Zytiga®) in metastatic Castration-Resistant Prostate Cancer (mCRPC)
-
Jun 15, 2018Safety Review Committee (SRC) recommends proceeding to the second dosing cohort of PCM-075 in combination with decitabine in dose-escalation phase of trial
-
May 17, 2018Safety Review Committee (SRC) recommends proceeding to the second dosing cohort of PCM-075 in combination with low-dose cytarabine (LDAC) in dose-escalation phase of trial
-
Apr 17, 2018Methodology to assess changes in leukemic cells, genomic alterations and pTCTP status for Phase 1b/2 Clinical Trial of PCM-075. Update on clinical trial recruitment.
-
Apr 16, 2018Combination of PCM-075, a highly-selective Polo-like Kinase 1 (PLK1) inhibitor, and Quizartinib resulted in 97% tumor growth inhibition and regression in FLT3 AML model
-
Feb 13, 2018Yale Cancer Center and Kansas University Cancer Center now actively screening and enrolling patients in Phase 1b/2 Study of PCM-075 in Acute Myeloid Leukemia (AML)
-
Feb 9, 2018Targeted treatment with highly-selective Polo-like Kinase 1 inhibitor PCM-075 in combination with Zytiga® (abiraterone acetate) may represent a new treatment option in CRPC
-
Jan 24, 2018PCM-075, Trovagene's highly-selective Polo-like Kinase 1 (PLK1) inhibitor may extend patient response to therapy when used in combination with Zytiga® (abiraterone) in mCRPC
-
Dec 21, 2017Activation of second trial site for Phase 1b/2 clinical trial of PCM-075, in combination with standard-of care, to evaluate dose and scheduling, and preliminary anti-leukemic activity
-
Dec 14, 2017PCM-075, Trovagene's Polo-like Kinase 1 (PLK1) inhibitor enhances activity of abiraterone in mCRPC tumor cells and may represent a novel combination treatment option in mCRPC
-
Dec 7, 2017Targeted treatment with highly selective Polo-like Kinase 1 inhibitor, PCM-075, may represent a new option in TNBC, particularly in combination with other abiraterone acetate
-
Nov 13, 2017Activation of first trial site for Phase 1b/2 clinical trial of PCM-075, in combination with standard-of care, to evaluate dose and scheduling, and preliminary anti-leukemic activity
-
Oct 18, 2017PCM-075 enhances activity of abiraterone in mCRPC tumors cells and may represent a novel treatment option to extend the benefit of anti-androgen therapy
-
Sep 20, 2017Dr. Athena Countouriotis joins Trovagene's Board of Directors, bringing significant experience in oncology clinical development and orphan indications
-
Aug 21, 2017Additionally, Trovagene announces PCM-075 synergy in combination with more than ten chemo and targeted therapeutics across a broad range of solid tumor and hematologic malignancies
-
Aug 16, 2017Human AML xenograft with FLT3 mutation shows PCM-075 in combination with Quizartinib resulted in 96% tumor growth inhibition with tumor regression
-
Jul 27, 2017PCM-075, in combination with decitabine, in patients with Acute Myeloid Leukemia (AML) for exploration of the safety, tolerability, dose and scheduling, and antitumor activity
-
Jul 25, 2017Greater selectivity for PLK1, potency, oral bioavailability and short half-life underscore PCM-075's potential as safe and effective treatment for solid tumor and hematological malignancies
-
May 25, 2017Study evaluated safety, dose limiting toxicities, related maximum tolerated dose and indication of anti-tumor activity in patients with advanced or metastatic solid tumors